Intelligent Bio Solutions (NASDAQ: INBS) details FY 2025 financial results

Rhea-AI Filing Summary

Intelligent Bio Solutions Inc. filed a current report to disclose that it issued a press release on August 15, 2025 announcing its financial results for the three months and full fiscal year ended June 30, 2025. The press release is attached as Exhibit 99.1.

The company states that the information in this report and the exhibit is being furnished, not filed, so it is not subject to certain liability provisions under U.S. securities laws and will not be incorporated into other filings unless specifically referenced.

false 0001725430 0001725430 2025-08-15 2025-08-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): August 15, 2025

INTELLIGENT BIO SOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39825		82-1512711
(State of Incorporation)		(Commission File Number)		(IRS employer identification no.)

135 West, 41st Street, 5th Floor

New York, NY 10036

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (646) 828-8258

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		INBS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 15, 2025, Intelligent Bio Solutions Inc. (the “Company”) issued a press release (the “Press Release”) announcing financial results for the three months and full fiscal year ended June 30, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference to such filing. The information in this report, including the exhibit hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended.

Item 9.01 Financial Statements and Exhibits.

No.		Description
99.1		Press Release, dated August 15, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 15, 2025
	INTELLIGENT BIO SOLUTIONS INC.
	By:	/s/ Spiro Sakiris
	Name:	Spiro Sakiris
	Title:	Chief Financial Officer

FAQ

What did Intelligent Bio Solutions (INBS) report in this 8-K filing?

Intelligent Bio Solutions reported that it issued a press release announcing its financial results for the three months and full fiscal year ended June 30, 2025, and furnished that press release as an exhibit.

What period do the reported Intelligent Bio Solutions (INBS) results cover?

The reported results cover both the three-month period and the full fiscal year ended June 30, 2025.

How can investors access the Intelligent Bio Solutions (INBS) financial results mentioned in the 8-K?

The detailed financial results are contained in the company’s press release, which is included as Exhibit 99.1 to the report.

Is the Intelligent Bio Solutions (INBS) earnings information considered "filed" with the SEC?

No. The company specifies that the information in the report and its exhibit is being furnished, not filed, and is not subject to certain liability provisions of the securities laws.

Will the Intelligent Bio Solutions (INBS) press release be automatically incorporated into other SEC filings?

No. The company states that the information will not be incorporated by reference into other filings unless expressly incorporated by specific reference.

Which exhibit contains the Intelligent Bio Solutions (INBS) press release?

Exhibit 99.1 contains the press release dated August 15, 2025 that presents the company’s financial results.